Dysregulated incretin signaling also affects hepatic gluconeogenesis and lipid metabolism, contributing to the increased prevalence of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome in PCOS patients [230,231,232]. This evidence concerns the gene GCG and polycystic ovary syndrome.